Oct. 7 at 7:49 PM
Deep Value Daily –
$CRIS
Current
$1.61 vs Alpha Spread → Worst Case
$7.35, Base Case
$15.07, Best Case
$23.48
Undervalue %: WC 78.10%, Base 89.32%, Best 93.14%
Country: United States
Pros: Clinical-stage oncology pipeline (Emavusertib IRAK4, Fimepinostat, CA-170); recent FDA/EMA alignment for accelerated path in PCNSL; the base of model implies ~5–10× upside.
Cons: Recently raised
$7M via stock + warrant offering — heavy dilution risk; operating losses, burn, thin liquidity; clinical trial risk is binary for biotech.
Entry Idea: Watch reclaim above
$2.50 with volume; invalidate if it falls and holds <
$1.20.
Stay disciplined, keep hunting, keep surviving.
#DeepValueDaily #IntrinsicValue #SmallCaps
